Document is current
Any future updates will be listed below
-
Authors
Zeineddine, Fadl A.
Zeineddine, Mohammad A. https://orcid.org/0000-0001-8075-765X
Yousef, Abdelrahman https://orcid.org/0000-0001-7761-8149
Gu, Yue https://orcid.org/0000-0002-9642-0338
Chowdhury, Saikat https://orcid.org/0000-0002-0783-3959
Dasari, Arvind
Huey, Ryan W. https://orcid.org/0000-0002-7887-8484
Johnson, Benny
Kee, Bryan
Lee, Michael S.
Morelli, Maria Pia
Morris, Van K.
Overman, Michael J.
Parseghian, Christine
Raghav, Kanwal https://orcid.org/0000-0003-1311-4173
Willis, Jason https://orcid.org/0000-0001-8238-8552
Wolff, Robert A.
Kawaguchi, Yoshikuni https://orcid.org/0000-0003-2986-3224
Vauthey, Jean-Nicolas
Sun, Ryan
Kopetz, Scott
Shen, John Paul https://orcid.org/0000-0003-4588-2775
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas
U.S. Department of Health & Human Services | NIH | National Cancer Institute (SPORE P50CA221707)
- License Information
-
More Information
Article History
Received: 12 May 2022
Accepted: 16 January 2023
First Online: 13 February 2023
Competing interests
: AD is an advisor for HutchMed; Personalis Inc; AAA / Novartis; Ipsen and receives research funding from Eisai, HutchMed; Guardant Health; Xencor. BJ is an advisor for Gritstone bio; Incyte; Taiho Oncology; Insmed Oncology and research funding from Bristol-Myers Squibb; Syntrix; Gateway for Cancer Research. CP receives honoraria from Merck and Pfizer and research support from Amgen, Inc and Lilly. KR is an advisor for Bayer; Daiichi; AstraZeneca; Seattle Genetics and receives research funding from Guardant, Bayer; Daiichi; AstraZeneca; Amgen, Medimmune. MSL is an advisor for Pfizer; Delcath and receives research funding from EMD Serono, Inc; Amgen, Inc, Bristol-Myers Squibb Co; Pfizer, Inc; Genentech/Roche; Exelixis, Inc, and Rafael Pharmaceuticals; MO is an advisor for Takeda Pharmaceuticals; Pfizer; Merck; Glaxosmithkline and receives research funding from Roche; Takeda; Merck; BMS. VM is an advisor for Incyte; SERVIER; Boehringer Ingelheim; Axiom Healthcare Strategies; BioMedical Insights; Bicara Therapeutics and receives research funding from Immatics; Bristol-Myers Squibb; EMD Serono; Pfizer; BioNTech AG; Bicara Therapeutics. SK has ownership interest in Lutris, Iylon, Frontier Medicines, Xilis, Navire and is a consultant for Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, AstraZeneca/MedImmune, Bayer Health, Redx Pharma, Ipsen, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, Abbvie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech, Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson/Janssen, Genomic Health, Frontier Medicines, Replimune, Taiho Pharmaceutical, Cardiff Oncology, Ono Pharmaceutical, Bristol-Myers Squibb-Medarex, Amgen, Tempus, Foundation Medicine, Harbinger Oncology, Inc, Takeda, CureTeq, Zentalis, Black Stone Therapeutics, NeoGenomics Laboratories, Accademia Nazionale Di Medicina, and receive research funding from Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyo; JPS is an advisor for Engine Biosciences and receives research funding from Celsius Therapeutics. The remaining authors declare no competing interests.
